News & Events

News

TriSalus Appoints Scott Davie As Chief Technology Officer

Appointment provides operational leadership for the Company’s therapeutic infusion delivery systems

June. 8, 2020–TriSalus Life Sciences (TriSalus), a company committed to transforming outcomes for patients with solid tumors, announces the appointment of Scott Davie to the role of Chief Technology Officer, deepening the company’s leadership capabilities as it builds an integrated therapeutic/drug delivery portfolio. As chief technology officer, Davie will oversee research and development of the company’s intravascular infusion systems powered by its proprietary Pressure Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology, as well as operations, pre-clinical execution, and management of the IP portfolio. A 25-year veteran of the medical device industry across multiple industry segments, Davie also will serve as site lead for the company’s Westminster, CO facility and report to the company’s President and Chief Executive Officer, Mary Szela.

“We’re thrilled to add Scott’s deep experience in medical device development and commercialization to the critical work underway at TriSalus. Our PEDD-based products have tremendous promise for treating solid tumors, and under his knowledge and leadership skills, we’re poised to help lead a transformation in cancer care,” said Szela. “Additionally, his experience in the U.S., Canadian, and Japanese markets is essential to supporting our global development efforts.”

Prior to joining TriSalus Life Sciences, Davie held a number of leadership positions at Medtronic creating and leading teams and engineering departments. He has delivered innovative, complex, therapeutic and diagnostic systems from conceptualization through market launch including implantable cardiac devices, AF ablation systems, and hospital based diagnostic platforms. His regulatory experience spans filings and registrations via 510k’s, PMA supplements, original PMAs, and CE Marks.

Davie earned his Bachelor of Science in Mechanical Engineering from MIT and his Master of Science in Mechanical Engineering from Stanford with a focus on Biomechanics and Electronics.

“As someone who’s watched cancer cut family member’s lives short, I am thrilled to be part of the TriSalus team and embrace the opportunity to dramatically improve therapeutic delivery and outcomes for these cancer patients,” said Davie.

About TriSalus
TriSalus Life Sciences is dedicated to improving patient outcomes in pancreatic and other highly intractable solid tumors. TriSalus Infusion Systems, powered by the proprietary Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology have the potential to improve the delivery and distribution of diagnostic agents, therapeutics, and immuno-stimulants into the tumor vasculature.
This innovative approach combines both physical and therapeutic modes of action to overcome inherent immune suppression within the tumor microenvironment and offers a new reason for hope among those suffering from solid tumors.
For more information, please visit  www.trisaluslifesci.com.

About Pressure-Enabled Drug Delivery (PEDD) with SmartValve Technology
The proprietary Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology features a self-expanding, nonocclusive, one-way valve which can infuse therapeutics into solid tumor vasculature at a pressure higher than the baseline mean.1 SmartValve devices have been shown to deliver more therapy into the tumor while preventing embolic reflux.2

 

1Data on file (CEA 001 trial) Study Design: Single patient infusion. Pressure continuously monitored during initial positioning at target site, deployment of the PEDD™ device, and infusion of 3 cc saline bolus. TriSalus™ Life Sciences, 2019.

2Titano et al Study Design: A retrospective, single-center study included 88 treatment-naive patients with solitary HCC tumors <6.5 cm who underwent treatment utilizing either SIS (n = 18) or standard EH microcatheters (n = 70). Twenty-three patients (5 SIS, 18 EH) received a liver transplant during the study, with 1 SIS and 6 EH patients excluded from the tumor necrosis analysis for receiving subsequent therapies prior to transplant. A pathologist performed a blinded review of the liver explant specimens to assess tumor necrosis and treatment distribution. Pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in SIS explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002). Titano JJ, et al. Cardiovasc Intervent Radiol. 2019;42:560-568.